Sulopenem is a carbapenem derivative in phase III clinical trials (2022) for the treatment of various gram-positive and gram-negative infections.
Machine-generated and unreviewed. Identity, structure and cross-references come straight from ChEBI's and CARD's own data; no curator has signed off on this record yet.
carbapenemARO:0000020
ARO:0000020| Molecular formula | C12H15NO5S3 |
|---|---|
| Charge | 0 |
| Average mass | 349.5 Da |
| Monoisotopic mass | 349.0112361 Da |
| Source | PubChem · retrieved 2026-08-29 |
| InChIKey | FLSUCZWOEMTFAQ-PRBGKLEPSA-N |
C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O
InChI=1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6+,7+,10-,21-/m1/s1
| Source | Native ID | Label | Minted CURIE | Version |
|---|---|---|---|---|
| ARO | ARO:3007143 |
sulopenem | antibioticmech:aro-f9ecce9898 |
2026-08-30 |
Seeded from data/raw/ inventories (ARO)
Re-seeded from updated data/raw/ inventories
Re-seeded from updated data/raw/ inventories